Watch GT 6 Pro: Huawei's Smartwatch Outperforms Apple and Samsung in Health
Huawei has entered the medical technology arena strongly, surpassing both Apple and Samsung, with the launch of an innovative feature to monitor the risk of diabetes on its smartwatch Watch GT 6 Pro.
The new feature relies on the "Diabetes Risk" application, which analyzes user metrics through photoplethysmography (PPG) technology and additional sensors over a period of 3 to 14 days.
Although it does not directly measure blood sugar levels and does not provide traditional values such as mmol/L or mg/dL, it represents an important step in assessing the likelihood of diabetes without the need for continuous finger pricking.
Huawei announced this feature during the 2026 Global Health Exhibition in Dubai, and it is currently available only on the Watch GT 6 Pro, with plans to expand it to other products in the future.
However, there are some important caveats:
• The feature is not available in all countries and regions, including the United States.
• No independent tests have yet been conducted to compare the accuracy of the watch with blood sample-based continuous glucose monitors.
As Apple and Samsung strive to develop non-invasive methods for diagnosing diabetes, these innovations indicate significant future leaps in wearable health devices.
If this feature proves effective, it could revolutionize the way diabetes risk is assessed, helping diabetes patients and individuals wishing to monitor their health daily without the need for traditional hospital tests.
